Clinical Trial Update: Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating whether adding ovarian function suppression to tamoxifen improves outcomes in young women with breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: Korean Breast Cancer Study Group | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN